Effect of low dose acetylsalicylic acid and anticoagulant on clinical outcomes in COVID-19, analytical cross-sectional study.
Muhammad B MalikSamar Ahmed AmerEric MerrellRonald RussoJeffrey B RileyAustin ScroElizabeth JamesAnderson AnuforoSoumya AdhikariRosalie SicilianoPhilip ChebayaEdward DarlingMichael KuhnGary NiemanAhmed ShawkatHani AiashPublished in: Health science reports (2022)
Low-dose ASA has a nonsignificant but potentially protective role in reducing the risk of COVID-19 related morbidity and mortality. Our data suggests a trend toward reduced 30-day readmission rates, ARDS, MICU admissions, need for mechanical ventilation, and mortality compared to the standard management protocol. Further randomized control trials are needed to establish causal effects.
Keyphrases
- mechanical ventilation
- low dose
- coronavirus disease
- acute respiratory distress syndrome
- sars cov
- intensive care unit
- high dose
- respiratory failure
- extracorporeal membrane oxygenation
- double blind
- open label
- randomized controlled trial
- atrial fibrillation
- venous thromboembolism
- cardiovascular events
- respiratory syndrome coronavirus
- electronic health record
- phase iii
- placebo controlled
- phase ii
- cardiovascular disease
- clinical trial
- big data
- risk factors
- type diabetes
- liquid chromatography
- artificial intelligence
- data analysis